Fig. 2: Timeline of key advancements in the treatment of BRAFV600E-mutant NSCLC.
From: BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape
Positive data readouts for BRAF-mutant NSCLC (blue) and approved treatments for BRAFV600E-mutant NSCLC (green) are shown. aBRAF inhibitors. bMEK inhibitors. cIn 2022, dabrafenib plus trametinib was approved for patients with unresectable metastatic BRAFV600E-mutant solid tumors who progressed on previous treatments and have no acceptable alternative option. dImmunotherapy that targets PD-1. eImmunotherapy that targets PD-L1.
